Spotlight
Learning from PD-1 Resistance: New Combination Strategies

https://doi.org/10.1016/j.molmed.2016.04.008Get rights and content

Only a minority of cancer patients respond to anti PD-1 immunotherapy. A recent study demonstrates that PD-1 therapy-resistant melanoma patients present distinct signatures of upregulated genes involved in immunosuppression, angiogenesis, monocyte and macrophage chemotaxis, extracellular matrix remodeling, and epithelial–mesenchymal transition (EMT). Combination targeting of these pathways with PD-1 may help overcome PD-1 resistance, thus producing effective antitumor immunity.

Section snippets

Acknowledgments

Research Support: DF/HCC Kidney Cancer SPORE P50CA101942 (G.J.F.). Research supported by Claudia Adams Barr Program for Innovative Cancer Research (K.M.).

References (10)

There are more references available in the full text version of this article.

Cited by (54)

  • The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors

    2022, Pharmacology and Therapeutics
    Citation Excerpt :

    Subsequent analyses showed that the combination of the interferon pathway activity and IPRES-related immunosuppressive stromal scores are accurate predictors of ICB response in melanoma, gastric and metastatic urothelial carcinoma (Cui et al., 2021; Jiang et al., 2018; Zeng et al., 2021). The biological processes under IPRES were dominated by angiogenesis, hypoxia, epithelial to mesenchymal transition (EMT), and extracellular matrix remodeling, all of which are immunosuppressive processes related to the TGF-β and VEGFA pathways (Bu et al., 2016; MacCarthy-Morrogh & Martin, 2020; Parayath, Padmakumar, Nair, Menon, & Amiji, 2020; Schäfer & Werner, 2008). Therapeutic agents targeting TGF-β and VEGFA, the representative pathways of IPRES, may synergize with existing immunotherapies to overcome ICB resistance.

  • Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizing nanocage therapeutics for immune-mediated elimination of colorectal cancer

    2021, Biomaterials
    Citation Excerpt :

    Clinical efficacy of immune checkpoint inhibitors (ICIs) has exhibited unprecedented results in the recent years, however, they have shown to generate no effectual responses against tumors with low active host immunity [1].

  • Synergistic combination of oncolytic virotherapy with CAR T-cell therapy

    2019, Progress in Molecular Biology and Translational Science
View all citing articles on Scopus
3

Co-first authors.

View full text